Erasca (NASDAQ:ERAS) Posts Earnings Results, Misses Estimates By $0.03 EPS

Erasca (NASDAQ:ERAS) issued its earnings results on Tuesday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03), FiscalAI reports.

Erasca Price Performance

ERAS traded up $0.19 during trading hours on Tuesday, reaching $18.31. 3,426,108 shares of the stock traded hands, compared to its average volume of 6,297,791. Erasca has a fifty-two week low of $1.33 and a fifty-two week high of $24.28. The company has a market cap of $5.69 billion, a price-to-earnings ratio of -19.69 and a beta of 0.66. The firm’s fifty day simple moving average is $16.89 and its two-hundred day simple moving average is $14.83.

Institutional Trading of Erasca

Several large investors have recently modified their holdings of ERAS. BNP Paribas Financial Markets lifted its stake in shares of Erasca by 58.0% in the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock worth $27,000 after acquiring an additional 7,923 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in Erasca during the 2nd quarter worth approximately $29,000. Russell Investments Group Ltd. purchased a new position in shares of Erasca during the 3rd quarter valued at approximately $31,000. Stifel Financial Corp purchased a new position in shares of Erasca during the 4th quarter valued at approximately $38,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Erasca during the fourth quarter worth approximately $38,000. 67.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on ERAS. Wall Street Zen downgraded Erasca from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Bank of America raised their price objective on Erasca from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, July 14th. Mizuho reduced their price objective on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. Finally, Morgan Stanley increased their target price on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a research note on Monday, July 20th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.64.

Key Erasca News

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: Encouraging ERAS-0015 data: Erasca reported second-quarter business updates highlighting compelling monotherapy efficacy in patients with second-line-or-later KRAS G12X pancreatic ductal adenocarcinoma, with continued favorable tolerability. The company also advanced its ERAS-0015 combination with panitumumab in colorectal cancer. The update may support confidence in the pipeline and the potential commercial value of the program. Erasca Reports Second Quarter 2026 Business Updates and Financial Results
• Positive Sentiment: New R&D leadership: Erasca appointed internationally recognized oncologist Charles S. Fuchs, M.D., M.P.H., as president of research and development. The appointment could strengthen clinical strategy, development execution and the company’s credibility with investors and potential partners. Erasca Strengthens R&D Leadership
• Neutral Sentiment: Employee inducement grants: The company announced equity awards under Nasdaq Listing Rule 5635(c)(4). The grants are intended to attract or retain employees, although they may create modest dilution for existing shareholders. Erasca Announces Inducement Grants
• Negative Sentiment: Litigation overhang: Several law firms announced or promoted a securities class action against Erasca concerning alleged investor misstatements about ERAS-0015’s competitive position, safety profile and intellectual-property protection. The repeated notices do not represent new findings by themselves, but the lawsuit could increase legal costs, reputational risk and uncertainty around the company’s prior disclosures. Class Action Lawsuit Filed Against Erasca

About Erasca

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.